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Effect of green tea and lycopene on the insulin-like growth
factor system: the ProDiet randomized controlled trial
Kalina M. Biernackaa,b,*, Jeff M.P. Hollya,*, Richard M. Martinb,c,
Aleksandra Frankowa,b, Caroline J. Bulla,c, Freddie C. Hamdye,f,
Jenny L. Donovanc, David E. Nealg,h, Chris Metcalfec,d,† and Athene Laneb,c,†
Whether prostate cancer (PCa) may be preventable by
dietary interventions can be assessed in randomized trials
using intermediate biomarkers of cancer risk or
progression. We investigated whether lycopene or green tea
modify circulating insulin-like growth factor (IGF) peptides
in men at increased risk of PCa. Participants (aged
50–69 years) in one centre in the UK wide PCa testing and
treatment trial (ProtecT) with prostate specific antigen
between 2.0 and 2.95 ng/ml or negative biopsies, were
randomized to daily lycopene (n= 44 assigned 15mg
capsules/day; 44 assigned a lycopene-rich diet; 45
assigned placebo) and green tea (n= 45 assigned 600mg/
day epigallocatechin gallate; 45 assigned green tea drink;
43 assigned placebo) for 6 months. The interventions
significantly elevated the primary outcomes, serum
epigallocatechin gallate and lycopene at 6 months of follow-
up. We report here an exploratory analysis in which serum
IGF-I, IGF-II, IGF binding protein (BP)-2 and IGFBP-3 were
measured at baseline and 6 months of postintervention. A
total of 133 men were randomized (34% of eligible men
approached) and 130 had follow-up IGF peptides (98%). In
intention-to-treat analyses, there was only weak evidence
that lycopene or green tea influenced some aspects of
serum IGF-I, IGF-II, IGFBP-2 or IGFBP-3. In men
randomized to lycopene supplements, IGFBP-2 was
nonsignificantly (50.9 ng/ml; 95% confidence interval:
− 51.2–152.9, P= 0.3) higher in comparison to placebo,
whereas in men randomized to green tea supplements,
IGFBP-3 was nonsignificantly (205.2 ng/ml; 95%
confidence interval: − 583.3–172.9, P= 0.3) lower than with
placebo. In this small, pilot randomized controlled trial, there
was little evidence that lycopene or green tea interventions
influenced serum levels of IGF-I, IGF-II, IGFBBP-3 and
IGFBP-2. However, the effects were imprecisely estimates
and some observed trends may justify larger
trials. European Journal of Cancer Prevention 00:000–000
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Introduction
Prostate cancer (PCa) is a leading cause of morbidity and
mortality among UK men (Cancer Research UK, 2016).
Nutrition, in particular adopting a western lifestyle, is
thought to be an important contributor to prostate carci-
nogenesis. The primary role of insulin-like growth factor
(IGF) ligands (IGF-I, IGF-II) is to regulate prenatal
and postnatal growth with binding proteins modulating
their action (Daughaday and Rotwein, 1989; Jones and
Clemmons, 1995). The IGF system also has an important
role in carcinogenesis through proliferation, antiapoptotic
and metabolic effects (Khandwala et al., 2000) and high
serum levels of IGF-I have been associated with risk of
various cancers, including PCa (Yu et al., 1999; Rowlands
et al., 2009; Young et al., 2012; Rowlands et al., 2013). In
turn, nutrition has an important role in regulating the
IGF system. It has, therefore, been hypothesized that
dietary modification could reduce neoplastic growth and
the risk of PCa by inhibiting both tumour initiation and
growth of small cancer foci via IGF-related pathways.
Laboratory and observational studies indicate that both
lycopene and green tea may possess this dual action on
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cancer initiation and growth, but robust evidence from
randomized controlled trials is needed to determine their
causal effects in free living humans (Syed et al., 2007).
Lycopene is a carotenoid found in tomatoes and tomato-
based products (Najm and Lie, 2008). In-vitro and in-vivo
studies suggest that lycopene is an antioxidant with poten-
tial anticancer effects (Wei and Giovannucci, 2012), inhi-
biting the viability of various human cancer cell lines,
including PCa (Teodoro et al., 2012). Supporting the
laboratory data, a meta-analysis of 17 epidemiological studies
indicated inverse associations of tomato or lycopene intake,
and serum lycopene levels, with PCa (Jinyao Chen and
Zhang, 2012). For nearly two decades studies have investi-
gated associations between one or more carotenoids and the
IGF axis. A recent cross-sectional study of 2742 men and
3316 women reported a 282 ng/ml [95% confidence interval
(CI): 273–292, Pfor trend=0.01] and 245 ng/ml (95% CI:
237–253, Pfor trend=0.02) increase of IGF-I with the highest
quintiles of lycopene in men and women, respectively. The
ratio IGF-I : IGFBP-3 was also increased by 0.24 (95% CI:
0.23–0.25, Pfor trend=0.01) and 0.2 (95% CI: 0.19–0.21, Pfor
trend=0.06) with highest quintiles of lycopene in men and
women, respectively. There was also a trend that lycopene
increases IGFBP-3 level but it was not conventionally
statistically significant (Diener and Rohrmann, 2016).
It has been suggested that green tea and its active com-
pound [epigallocatechin gallate (EGCG)], have numer-
ous metabolic benefits (Ahmad et al., 2015), including
in-vitro and in-vivo evidence that they reduce the pro-
gression and invasion of numerous cancers, including
PCa (Luo et al., 2010; Fujiki et al., 2015). These findings
have preliminary support from a small, short-term ran-
domized controlled trial in men with localized PCa, based
on biochemical recurrence as the outcome (Thomas et al.,
2014), and a recent meta-analysis of 21 epidemiological
studies (Fei et al., 2014). Green tea has also been linked
with the IGF axis in various cancers showing that EGCG
counteracted IGF-I mediated angiogenesis in lung can-
cer cells (Li et al., 2013) or was associated with reduction
of IGF-I receptor in pancreatic cancer cells (Vu et al.,
2010). In-vivo studies also showed a decrease of IGF-I
and restoration of IGFBP-3 levels after administering
green tea polyphenol mixture (containing 62% of EGCG)
to mice with transgenic adenocarcinoma of the prostate
for 24 weeks (Adhami et al., 2004).
To test the hypothesis that lycopene or green tea influ-
ence circulating IGF peptides in men at elevated risk of
cancer (defined pragmatically in our study as men with
prostate specific antigen (PSA) levels between 2.0 and
2.95 ng/ml or PSA≥ 3 ng/ml but negative biopsies), we
measured serum levels of IGF-I, IGF-II, IGF binding
protein (BP)-2 and IGFBP-3 at baseline and after
6 months of an intervention in which men were rando-
mized to daily lycopene and green tea (the ProDiet trial)
(Lane et al., 2010). Men adhered successfully to two
dietary interventions with significant elevation of the
primary outcomes, serum EGCG and lycopene levels at
6 months. Lycopene concentrations (µmol/l) were 25.4%
higher (95% CI: 1.07–1.46, P= 0.005) in men following
dietary advice and 41.9% higher (95% CI: 1.22–1.66,
P< 0.001) following supplementation, both compared
with placebo. Plasma EGCG levels in men assigned to
dietary advice or green tea supplementation were raised
by a median 22.1 nmol/l (95% CI: 2.59–41.61 nmol/l;
P= 0.026) and 9.5 nmol/l (95% CI: − 1.79–20.79 nmol/l;
P= 0.099) versus placebo, respectively (Lane et al., 2012).
Patients and methods
The ProDiet trial was nested within the ProtecT (Prostate
testing for Cancer and Treatment) trial (Lane et al., 2010;
Henning et al., 2015) of treatments for localized PCa for
men aged 50–69 years. The ProtecT men were recruited
between 2001 and 2009 from 347 randomly selected
general practices in the UK. In ProDiet, men with an
increased risk of PCa (defined below) were assessed for
their eligibility for entry into a double blind randomized
controlled trial of dietary modifications with green tea and
lycopene. The primary outcomes of this trial were feasi-
bility of randomization, and the impact of the interven-
tions on serum lycopene and EGCG levels after 6 months
of follow-up as a measure of compliance to interventions.
The IGF outcomes were exploratory (i.e. the prespecified
power of the trial was not based on these outcomes).
Men were selected for inclusion in this trial from the 469
invited men at one ProtecT centre who had a PSA level
between 2.0 and 2.95 ng/ml or a PSA of at least 3.0 ng/ml
with a negative biopsy between 2008 and 2009. This
group includes men with an elevated risk of PCa due to
possible hidden precursor conditions (e.g. high-grade
prostatic intraepithelial neoplasia) or small cancer foci in
men with PSA below 3 ng/ml or that was undetected by
biopsies. The following men were excluded: major co-
morbidities, other cancers or prior prostate malignancy; a
PSA level of at least 20 ng/ml; a history of allergic reac-
tions to green tea or lycopene containing products
(including guava, watermelon); and current medication
with finasteride or dutasteride (as these lower PSA
levels). The men received both written and verbal
information about the trial design and provided written
informed consent. The Trent Multicentre Research
Ethics Committee approved ProDiet (08/H0405/61).
Randomization
The men were randomly assigned to receive one of three
lycopene interventions – lycopene-rich diet: one or two
daily portions of tomato-based foods or dishes (n= 44),
lycopene capsules: one daily soft gel capsule of 15 mg
tomato-derived lycopene (Lyc-O-mato, Lycored Ltd,
Beer Sheva, Israel) (n= 44) or matched placebo capsule
(provided by Lycored Ltd) (n= 45) – and one of the
green tea interventions – green tea drink: two mugs or
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three cups of green tea daily (n= 45), green tea-derived
capsules (Frutarom Ltd, Reinach, Switzerland) at 600 mg
daily (n= 45), or matched placebo capsules (provided by
Frutarom Ltd) (n= 43). Participants were provided with
green tea (teabags and capsules) and lycopene capsules
or placebos at randomization and at months 1 and 3 into
the intervention. To aid compliance, a weekly record
sheet was also provided for participants. In the lycopene
intervention arm, men were also informed that cooking
tomatoes increases lycopene’s bioavailability and that
other sources of lycopene, such as watermelon or pink
grapefruit, have a lower lycopene content compared with
tomatoes.
Food frequency questionnaire
Men filled in a validated 89 item self-completed food
frequency questionnaire (FFQ) to record their average
food intake over the 6 months before the trial (baseline
assessment). Estimated daily intake of nutrients was
calculated using a combination of estimated portion size
from the FFQ and published composition of food data
(McCance and Great Bristain, 2004). Any participants
with at least 20 items missing from the FFQ had all
nutrients recoded to missing, as previous research indi-
cates that a missing response does not equate to ‘never’
in FFQs (Henning et al., 2015). We used these data to
derive intakes of: calcium (mg), animal protein (g), total
protein (g) and total carbohydrates (g).
Measurement of other baseline characteristics
All participants were asked to complete a questionnaire on
family history of PCa, self-reported diabetes and socio-
demographic status. BMI was calculated from self-reported
height and weight as weight over height squared (kg/m2).
Alcohol intake was estimated from the number of wine, beer
or spirits units consumed and the amount of alcohol (g) per
drink was calculated and reported as number of units of total
alcohol per week. Smoking was categorized as: never, ever
and current smokers. PSA was measured in the local PSA
testing clinic at recruitment and at 6 months.
Specimen collection and insulin-like growth factor-
system assays
Nonfasted blood samples for IGF and IGFBPs measures
were taken from men at their first appointment before
diagnosis (baseline) and at the 6 months postrandomization
follow-up appointment. The samples were allowed to clot,
centrifuged at 1640g for 20min within 2 h of collection and
stored in −80°C until assayed. The samples underwent two
freeze-thaw cycles before the IGF assays, which has pre-
viously been shown to have no effect on IGF or IGFBP-3
levels (Yu et al., 1999). Circulating IGF-I, IGF-II (free and
bound peptides) and IGFBP-3 (including all forms that
had undergone minor fragmentations) levels were assessed
using in-house radioimmunoassays by technicians blinded
to randomization status: results used in the analysis were
based on the mean of three measures. IGFBP-2 was
assessed using an enzyme-linked immunosorbent assay
(DY674; R&D Systems, Abingdon, UK); IGFBP-2 results
used in the analysis were based on the mean of two mea-
sures. The average intra-assay coefficients of variation for
IGF-I, IGF-II, IGFBP-3 and IGFBP-2 were 7, 9.5, 6.3 and
0.7%, respectively. The overall interassay coefficients of
variation were 9.9, 11.3, 11.4 and 2.85%, respectively.
Statistical analysis
We performed all statistical analysis in STATA version
2013 (StataCorp LLC, Collage Station, Texas, USA).
Serum IGF-I, IGF-II and IGFBP-3 levels were approxi-
mately normally distributed. Serum IGFBP-2 levels were
slightly positively skewed, but residuals were normally
distributed with no major outliers, and we, therefore, ana-
lysed the raw data rather than perform a transformation that
would be more difficult to interpret. We used linear
regression to estimate associations of the interventions with
follow-up IGFs and IGFBPs. There were no baseline
imbalances in the covariates apart from diabetes status in
green tea arm and so the primary analyses are unadjusted.
We used analysis of variance to assess heterogeneity. In a
secondary analysis, we controlled for measured baseline
variables and in a sensitivity analysis we checked whether
excluding men with diabetes made any difference to the
results. We tested for interaction between the lycopene and
green tea interventions on IGFs and IGFBPs using like-
lihood ratio tests.
Results
At baseline, 120 men had IGFs measured, the missing
data being due to inadequate serum sample collected. The
120 men were allocated to: (i) green tea – either as a green
tea supplement (n= 41), green tea drink (n= 41) or pla-
cebo (n= 38); and (ii) lycopene, either as a lycopene sup-
plement (n= 41), a lycopene-rich diet (n= 42) or placebo
(n= 37). After 6 months of intervention, 130 men had
follow-up IGFs measured: green tea supplement (n= 45),
green tea drink (n= 44) or placebo (n= 41) and lycopene
supplement (n= 41), lycopene-rich diet (n= 44) or placebo
(n= 45) (Fig. 1).
Potential confounders (age, BMI and PSA) and IGF levels
at baseline were mostly equally distributed between the
lycopene and green tea (Table 1) intervention arms, con-
firming the success of randomization. We have also
examined the potential for confounding due to family
history of PCa, social class, smoking, alcohol and diabetes:
all these variables were equally distributed between the
groups and their inclusion in the models did not alter the
results (data not shown). Only two men had diabetes and
excluding them made no material difference to the results
(Supplementary Table 1, Supplemental digital content 1,
http://links.lww.com/EJCP/A225).
Table 2 shows there was little statistical evidence of any
effect of the lycopene intervention (as a dietary modification
or supplement vs. placebo) or green tea intervention (as a
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green tea drink or supplementation vs. placebo) on IGF-I,
IGF-II, IGFBP-3 or IGFBP-2. In men randomized to lyco-
pene supplements, IGFBP-2 was nonsignificantly 50.9 ng/ml
(95% CI: −51.2–152.9, P=0.3) higher in comparison to
placebo, and in men randomized to green tea supplements,
IGFBP-3 was nonsignificantly 205.2 ng/ml (95% CI:
−583.3–172.9, P=0.3) lower than with placebo. There was
no evidence of interaction between the lycopene and green
Table 1 Distribution of each of the covariables and insulin-like growth factors in lycopene and green tea trial arms at baseline (120 men at
risk of prostate cancer)
Characteristics
Dietary advice
(N=42)
[mean (SD)
or n (%)]
Supplement
(N=41)
[mean (SD)
or n (%)]
Placebo
(N=37)
[mean (SD)
or n (%)]
Lycopene
Age (years) 42 64 (4.7) 41 65 (6.2) 37 64 (4.9)
BMI (kg/m2) 32 27 (3.7) 31 26 (2.7) 29 28 (4.2)
IGF-I (ng/ml) 42 238 (58.9) 41 240 (67.5) 37 234 (52.9)
IGF-II (ng/ml) 42 589 (181.1) 41 574 (195.9) 37 537 (148.5)
IGFBP-3 (ng/ml) 42 4467 (903) 41 4323 (969.3) 37 4263 (831.5)
IGFBP-2 (ng/ml) 42 491 (223.5) 41 546 (303.2) 37 461 (248)
PSA (ng/ml)
2.0 to <3.0 29 2.3 (0.3) 24 2.3 (0.3) 25 2.4 (0.3)
≥3.0 to <20 13 4.2 (1.2) 17 5.5 (3.1) 13 4.3 (1.4)
N=41 N=41 N=38
Green tea
Age (years) 41 64 (5.5) 41 64 (4.5) 38 64 (5.8)
BMI (kg/m2) 33 26.4 (3.5) 27 28 (3.6) 32 27 (3.8)
IGF-I (ng/ml) 41 245 (65.3) 41 232 (49.5) 38 235 (64.5)
IGF-II (ng/ml) 41 582 (199.3) 41 563 (169.9) 38 558 (162.1)
IGFBP-3 (ng/ml) 41 4401 (800.8) 41 4310 (1029.7) 38 4353 (878.3)
IGFBP-2 (ng/ml) 41 453 (216.9) 42 503 (270.5) 38 549 (289.2)
PSA (ng/ml)
2.0 to <3.0 25 2.3 (0.3) 30 2.3 (0.3) 23 2.4 (0.3)
≥3.0 to <20 16 4.5 (1.9) 12 5.3 (2.9) 15 4.5 (2)
IGFBP, insulin-like growth factor binding protein; IGF, insulin-like growth factor 1; PSA, prostate specific antigen.
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tea interventions on any of the IGF peptides (all Pfor
interaction>0.25).
Discussion
Main finding
In this small, pilot randomized controlled trial, there was
no statistical evidence that increased tomato intake,
lycopene supplementation, green tea drink or green tea
supplementation influenced IGF-I, IGF-II or IGFBP-3
and IGFBP-2. However, the sample size in this pilot was
small and thus, effect estimates were imprecisely esti-
mated (wide CIs). There was suggestive evidence that in
men randomized to lycopene supplements, IGFBP-2 was
higher in comparison to placebo, and in men randomized
to green tea supplements, IGFBP-3 was lower than with
placebo.
Comparison with the literature
A meta-analysis of 11 239 cases, suggested that the risk of
aggressive PCa in men within the highest versus lowest
quintile of lycopene intake was 0.65 (95% CI: 0.46–0.91)
(Key et al., 2015). However, a more recent post-hoc
analysis from the Procomb trial did not show evidence
for or against selenium and lycopene supplementation
with PCa patients (Morgia et al., 2017). In the Procomb
trial, daily lycopene intake was given at a dose of 5 mg for
a year compared with 15 mg of lycopene daily in our trial.
In another meta-analysis, consumption of green tea was
found to have a protective effect on risk of PCa (odds
ratio= 0.43, 95% CI: 0.25–0.73) (Zheng et al., 2011).
Drinking green tea (six cups per day) was also associated
with a reduction in PSA levels (Henning et al., 2015).
In-keeping with our findings, an open-label study of 26
men with PCa showed that short-term (6 weeks on average)
supplementation with EGCG (800mg daily) resulted in a
reduction in IGF-I serum level (SD) by 28 ng/ml (57.2),
IGFBP-3 by 291 ng/ml (606) and IGF-I : IGFBP-3 ratio by
0.0029 (0.0123) (McLarty et al., 2009). Our study and others
are relatively small in size and may justify larger trials to
verify that they are not simply chance.
In relation to the lycopene intervention, there was little
evidence of an association with IGF-I, IGF-II or IGFBP-
3 levels, but weak, imprecise evidence of an effect on
IGFBP-2. Other studies showed no effect of lycopene on
IGF-I, IGF-II or IGFBP-3 in patients with colorectal
cancer (Vrieling et al., 2007), no effect on IGF-I in breast
cancer patients (Voskuil et al., 2008) and no effects on
IGF-I in healthy participants (Riso et al., 2006). A small
study of 58 men with high-grade prostatic intraepithelial
neoplasia taking lycopene (30 mg/day) over the same
period (6 months) as this study, found no changes in
serum IGF-I (P= 0.99) and IGFBP-3 (P= 0.53) levels
between pretreatment and post-treatment groups (Gann
et al., 2015). Another study showed no effect on IGF-I
(P= 0.93) and IGF-I receptor (P= 0.53) in group of 22
men with favourable risk of PCa when on 3 monthsTa
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intervention with lycopene (30 mg/day) versus placebo
(Chan et al., 2011). Men and women with colorectal
cancer, randomly assigned to lycopene capsules for
8 weeks had increased levels of serum IGFBP-2 (by
8.2%, 95% CI: 0.7–15.6% for men and 7.8%, 95% CI:
− 5.0–20.6% for women). This increase in circulating
IGFBP-2 could potentially reduce IGF-I bioavailability
(Gann et al., 2015). However, in our study there was no
clear statistical evidence that the lycopene intervention
impacted IGFBP-2.
There are numerous observational studies in relation to
nutrition and PCa but many of them are likely to be
confounded by diet itself, physical activity and other
common causes of both nutritional exposures and PCa. A
meta-analysis of observational studies showed a pooled
odds ratio estimate for PCa in the highest versus non/
lowest green tea consumption of 0.72 (95% CI: 0.45–1.15)
(Zheng et al., 2011). Another meta-analysis indicated a
beneficial effect of tomatoes (but not lycopene) in rela-
tion to risk of PCa with pooled risk estimates of 0.81 (95%
CI: 0.69–1.06, P= 0.09) and 0.97 (95% CI: 0.88–1.08,
P=0.52), respectively (Jinyao Chen and Zhang, 2012).
However, we cannot speculate that green tea or lycopene
intervention modify the risk of PCa via the IGF system
based on our results.
The major strength of our study is the random assignment,
and baseline IGFs, IGFBPs and covariates were equally
distributed among trial arms suggesting successful rando-
mization. Another strength was the good adherence to the
intervention as evidenced by the serum levels of lycopene
and EGCC plus the effect of supplementation was assessed
with both capsular and dietary options. Detection bias was
excluded as all staff was blinded to randomization. The
major weakness is that the trial was not set up to investigate
IGFs as a primary outcome and was designed as a feasibility
pilot study. Therefore, wemay not have been able to detect
important effects that may be seen in adequately powered
trials. Hence, our findings are exploratory.
Conclusion
In this small pilot, randomized controlled trial, there was
no clear evidence that tomato-enriched diet, lycopene
supplementation, or a green tea intervention (drink or
tablets) influenced IGF-I, IGF-II, IGFBP-3 or IGFBP-2
serum levels.
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